ASHBURN, Va., Feb. 2 /PRNewswire/ -- Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed two additional distribution agreements for its CollaRx GENTAMICIN SURGICAL IMPLANT in Yemen and Jordan. In addition to these new arrangements, the Company has two existing partnerships in place in the Middle East, furthering its presence in this territory.
The product is indicated for the treatment and prevention of post- operative acquired infection. Innocoll, Inc. acquired the product rights from Essex Chemis AG, an affiliated company of Schering-Plough Corporation and has since assumed all sales, marketing and distribution activities for the product.
Dr. Michael Myers, President and CEO of Innocoll, Inc., stated, "We have identified the Middle East as a strategically important market for Innocoll. These new agreements coupled with our existing partnerships lay a strong foundation for the five to six pipeline products we plan to commercialize in the next 12-18 months."
Denise Carter, President of Innocoll Pharmaceuticals, said, "Our sales and marketing efforts are intensifying, as we continue to enter new markets. We are pleased with our continued success, as we advance our international marketing plans, in the hospital specialty pharmaceutical market."
The product was developed using Innocoll's proprietary collagen-based technology, CollaRx(TM), and has been approved in 49 countries. It is marketed under the following different trade names (COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), CRONOCOL(R)) in Europe, Central and South America, the Middle East, Africa and Asia.
About GENTAMICIN SURGICAL IMPLANT
GENTAMICIN SURGICAL IMPLANT is a biodegradable leave-behind implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin, and is indicated as an adjunct to systemic antibiotic therapy for the treatment and prevention of post-surgical acquired infection in both hard and soft tissues. It is based on Innocoll's CollaRx(TM) technology, a proprietary collagen-based system which locally delivers a wide variety of drug products, and can be formulated for implantable or topical application as a lyophilized sponge or as a cast film.
About Innocoll, Inc.
Innocoll is a privately held, fully integrated, global, hospital specialty pharmaceutical company specializing in surgical and dermatological products. It develops and markets internationally a range of medical products using its proprietary collagen-based technologies, CollaRx(TM) and LiquiColl(R). For more information, please visit http://www.innocoll.com. For product or pipeline information, please visit http://www.innocoll-pharma.com.
Innocoll, Inc.CONTACT: Michelle Cox, Marketing Manager, Innocoll Pharmaceuticals,+353(0)90 648 6282, or mcox@innocoll-pharma.com
